Our antibody combination is not currently authorized for use in any U.S. region. Please refer to the authorized Fact Sheet and FDA statement for additional details.
Learn More

Transcript

RGC efforts and expertise

Identifying Genetic Targets
>50 protectives variants
~30 drug targets advanced into pipeline

Predicting Disease Risk
Polygenic risk scores for Coronary Artery Disease, COVID-19, psychiatric disorders

Supporting Clinical Programs
Itepekimab for COPD
ODYSSEY trials design (Acute Coronary Syndrome)

Back
to top